Posts by: Marta Figueiredo

Marta Figueiredo

Marta Figueiredo holds a BSc in Biology and a MSc in Evolutionary and Developmental Biology from the University of Lisbon, Portugal. She is currently finishing her PhD in Biomedical Sciences at the University of Lisbon, where she focused her research on the role of several signalling pathways in thymus and parathyroid glands embryonic development.

February 14, 2020February 14, 2020

Iron Deficiency Common Among CF Patients and Requires Routine Screening and Guidelines, Study Suggests

cystic fibrosis, News

Iron deficiency is common among adults with stable cystic fibrosis (CF) and is significantly associated with anemia, vitamin A deficiency, antacids use, and moderate to severe lung disease, a ... Read more

January 31, 2020January 31, 2020

S. pseudopneumoniae Bacteria Can Cause Pulmonary Exacerbations in CF Patients, Study Finds

cystic fibrosis, News

Streptococcus pseudopneumoniae should be included in the panel of opportunistic bacteria causing pulmonary exacerbations among those with cystic fibrosis (CF), according to a small French study. The study, “Streptococcus ... Read more

January 21, 2020January 22, 2020

Enterprise’s ETX001 Targeting Chloride Channel Shows Promise for CF in Preclinical Studies

cystic fibrosis, News

Enterprise Therapeutics‘ experimental compound called ETX001 was able to increase airway fluid secretion and mucus clearance in preclinical models of cystic fibrosis (CF), a study reports. ETX001 is a ... Read more

November 20, 2019November 20, 2019

CF-related Diabetes Affects Girls More Often and at Younger Age than Boys, European Study Shows

cystic fibrosis, News

Girls with cystic fibrosis-related diabetes (CFRD) are exposed to risk factors of early death — including chronic infections, poor lung function, and poor nutrition — at a significantly higher proportion and ... Read more

November 7, 2019November 7, 2019

Eloxx Presents Positive Preclinical and Clinical Data of CF Therapy Candidate ELX-02

cystic fibrosis, News

Eloxx Pharmaceuticals presented additional positive preclinical and clinical data for ELX-02, its lead treatment candidate for cystic fibrosis (CF), reinforcing the therapy’s safety and tolerability in humans and its ability to increase ... Read more

October 4, 2019October 4, 2019

Patient-derived Mini-organs Work as ‘Avatars’ to Test CF Treatments

cystic fibrosis

Researchers in Australia are growing mini gut and lung “avatars” derived from cells of children with cystic fibrosis (CF) to predict their response to current and potential medications. This ... Read more

January 15, 2019January 23, 2019

Immunotherapy May Be Promising Strategy to Treat Chronic Infections of P. aeruginosa in CF Patients

cystic fibrosis, News

Blocking the interaction between two molecules involved in immune restraining mechanisms — called PD-1 and PD-L1 — may be an effective therapeutic strategy to boost the immune system and ... Read more

August 17, 2018

FDA Expands Kalydeco’s Approval to 1-year-old Toddlers with Cystic Fibrosis

News

The U.S. Food and Drug Administration (FDA) has approved Kalydeco (ivacaftor) as the first-ever therapy to treat the underlying cause of cystic fibrosis (CF) in 1-year-old toddlers, Vertex Pharmaceuticals announced. “Parents ... Read more

January 22, 2018January 22, 2018

Synspira Therapy Eliminates Antibiotic-resistant Lung Bacteria, Study Shows

cystic fibrosis, News

A therapy whose developers say could revolutionize the battle against antibiotic-resistant lung infections in cystic fibrosis patients eliminated resistant Staphylococcus aureus in a lab, a study reports. The finding dealt with Synspira’s polycationic ... Read more

December 18, 2017December 18, 2017

Cancer Gene, PTEN, Appears to Work with CFTR to Prevent Lung Infections, Study Reports

cystic fibrosis, News

One of the most frequently mutated genes in cancer, PTEN, in involved in the repeated lung infections that trouble cystic fibrosis patients — not because PTEN is abnormal in ... Read more